BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-3111
BEIJING, March 07, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (Nasdaq:BGNE), (“BeiGene”) a clinical-stage biopharmaceutical company focused on developing molecularly-targeted and immuno-oncological drugs for the treatment of cancer, today announced that it has …